Orquest plans launch in 2000 for Healos:
This article was originally published in Clinica
Executive Summary
Orquest, a Mountain View, California-based orthobiologics company, plans to launch its Healos bone graft substitute for spinal fusion in Europe next year. The company has a strategic alliance with Sulzer Spine-Tech for the CE-marked product, which is being evaluated for use with the BAK line of interbody fusion cages. The company is also developing an integrated growth differentiation factor-5, Healos/GDF-5, as a replacement for autograft. Another product, Ossigel, is designed to accelerate fracture healing by stimulating cell division and blood vessel formation within the fracture site. Ossigel, which is an injectable formulation of basic fibroblast growth factor and hyaluronic acid gel, is currently in clinical trials in the US and Europe.